Stereotaxis Reports 2025 Third Quarter Financial Results

Rhea-AI Summary

Stereotaxis (NYSE: STXS) reported results for the quarter ended September 30, 2025: total revenue $7.5M (Systems $1.9M; Recurring $5.6M). Gross margin was 55% (recurring 67%, systems 19%). Operating loss was $6.6M and net loss was $6.5M, with adjusted operating loss excl. non-cash charges of $2.5M. Negative free cash flow for Q3 was $4.2M. Cash on hand was $10.5M (pro forma $14.5M including an upcoming $4M financing tranche).

Operational highlights include FDA clearance for GenesisX, CE Mark and FDA submission for Synchrony, early commercial sales of MAGiC and MAGiC Sweep (>$300k revenue in first two months), and two Genesis orders in Europe. Company expects Q4 revenue >$9M and full-year 2025 revenue growth >20%.

Positive

• Recurring revenue +16.7% YoY (Q3: $5.6M vs $4.8M)
• Gross margin on recurring revenue at 67%
• FDA clearance for GenesisX robotic system
• MAGiC Sweep generated >$300k revenue in first two months
• Pro forma cash $14.5M including $4M upcoming financing
• Company expects Q4 revenue >$9M and full-year 2025 growth >20%

Negative

• Total revenue down ~18.8% YoY (Q3: $7.46M vs $9.20M)
• System revenue declined ~57.6% YoY (Q3: $1.86M vs $4.39M)
• Operating loss of $6.6M and net loss of $6.5M in Q3
• Negative free cash flow of $4.2M in Q3
• System gross margin low at 19%, impacted by fixed overhead

Insights

Senior Medical Device Financial Analyst

Stereotaxis posted mixed Q3 results: product approvals and early MAGiC sales offset lower total revenue; guidance targets stronger Q4.

Stereotaxis generated $7.5 million in revenue for the third quarter, with $1.9 million in system revenue and $5.6 million in recurring revenue; recurring margin was reported at 67% while system margin was 19%. The company recognized early commercial revenue from newly launched devices (MAGiC and MAGiC Sweep) and disclosed recent U.S. FDA clearance for the GenesisX system and CE Mark / FDA submission activity for Synchrony, which directly support near-term product sales and recurring consumable revenue.

The headline dynamics are mixed: short-term commercial traction and regulatory clearances are positive facts, but total quarter revenue declined versus the prior-year quarter in the consolidated table. Operating and net losses persisted (operating loss ~($6.6 million)), adjusted operating expenses fell to $6.6 million excluding non-cash items, and cash was $10.5 million at quarter end with an additional $4 million expected from a financing closing. These facts imply the business still depends on accelerating system placements, scaling production to improve system gross margins, and execution of the announced financing to sustain operations.

Concrete items to watch over the next quarter include the company’s Q4 2025 revenue realization (guidance: >$9 million and system revenue ~$3 million), recognition of the additional $4 million financing proceeds this month, and progress on regulatory reviews and catheter launches that would expand recurring revenue. Monitor quarterly gross-margin trends, recurring revenue growth, and cash runway as near-term signals of whether regulatory wins translate into profitable commercial scale.

ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025.

“We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones,” said David Fischel, Chairman and CEO. “This is an exciting milestone-rich period in which we are demonstrating the tangible reality and initial commercial impact of our comprehensive innovation strategy.”

“Our commercial progress includes two Genesis robotic systems ordered by hospitals since our last quarterly call, with both orders from European hospitals establishing entirely new robotic programs. Third quarter recurring revenue reflects summer seasonality in procedure volumes counteracted by positive momentum with Map-iT and the early launches of MAGiC and MAGiC Sweep. MAGiC Sweep has seen particularly high interest following recent FDA clearance, with over three hundred thousand dollars in revenue within the first two months of launch. We are beginning to build a clinically and commercially impactful catheter portfolio.”

“An accelerating pace of regulatory and development activity is advancing concurrent with these commercial efforts. We were pleased yesterday to announce U.S. FDA regulatory clearance for the GenesisX robotic system. We recently announced European CE Mark receipt and FDA submission for our Synchrony digital cath lab technology. We continue to work on multiple regulatory reviews for new electrophysiology and vascular catheters, while simultaneously advancing a pipeline of catheter innovations, which will contribute to commercial results in the short and medium term. Notable among these is the ongoing review of MAGiC in the U.S. and the recently announced collaboration with CardioFocus to advance the first robotically-navigated pulsed-field ablation electrophysiology catheter solution.”

2025 Third Quarter Financial Results
Revenue for the third quarter of 2025 totaled $7.5 million. System revenue of $1.9 million and recurring revenue of $5.6 million, compared to $4.4 million and $4.8 million, respectively, in the prior year third quarter. System revenue reflects partial revenue recognition on one capital system. Recurring revenue growth reflects contributions from a full quarter of Map-iT catheter revenue and initial sales of Stereotaxis’ new proprietary robotically navigated devices, the MAGiC ablation catheter and MAGiC Sweep high-density mapping catheter.

Gross margin for the third quarter was 55% of revenue. Recurring revenue gross margin was 67% and system gross margin was 19%. Gross margins remain impacted by fixed overhead allocated over low production levels.

Operating expenses in the third quarter of $10.7 million included $4.1 million in non-cash charges for stock compensation expense, mark-to-market adjustment for acquisition related contingent earnout consideration, and amortization of acquired intangible assets. Increased operating expenses include an adjustment on acquisition related contingent earnout consideration. Excluding these non-cash charges, adjusted operating expenses in the quarter were $6.6 million, a decrease from $7.2 million in the prior year third quarter primarily due to lower general and administrative expenses.

Operating loss and net loss in the third quarter of 2025 were ($6.6) million and ($6.5) million, respectively, compared to ($6.3) million and ($6.2) million in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash charges, were ($2.5) million and ($2.4) million, respectively, compared to ($3.1) million and ($3.0) million in the previous year. Negative free cash flow for the third quarter was consistent with the previous year at ($4.2) million.

Cash Balance and Liquidity
At September 30, 2025, Stereotaxis had cash and cash equivalents of $10.5 million and no debt. Including the $4 million Stereotaxis will receive in the upcoming second closing of the registered direct financing announced in July, Stereotaxis would have had $14.5 million in cash and no debt.

Forward Looking Expectations
Stereotaxis expects revenue in the fourth quarter of this year to exceed $9 million, with system revenue of approximately $3 million and recurring revenue greater than $6 million. This supports annual revenue growth for the current year of over 20%, in-line with previous guidance of double-digit revenue growth for the full year 2025. Sustained growth of both system and recurring revenue is expected in 2026, with quarterly revenue surpassing an average of $10 million per quarter. Stereotaxis will receive an additional $4 million in proceeds this month from the equity financing announced in July. Its balance sheet allows it to advance its transformative product ecosystem to market, fund its commercialization, and achieve profitability.

Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, November 11, 2025, at 4:30 p.m. Eastern Time. To access the conference call, dial 800-715-9871 (US and Canada) or 646-307-1963 (International) and give the participant pass code 4402192. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.

_{This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions, including tariffs, on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.}

Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly R. Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

Stereotaxis, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except share and per share amounts)	Three Months Ended September 30,								Nine Months Ended September 30,
		2025				2024				2025				2024
Revenue:
Systems	$	1,861			$	4,391			$	6,863				7,243
Disposables, service and accessories		5,603				4,805				16,872				13,335
Total revenue		7,464				9,196				23,735				20,578
Cost of revenue:
Systems		1,510				3,673				5,543				5,760
Disposables, service and accessories		1,853				1,424				5,448				3,440
Total cost of revenue		3,363				5,097				10,991				9,200
Gross margin		4,101				4,099				12,744				11,378
Operating expenses:
Research and development		2,546				2,454				6,673				6,970
Sales and marketing		2,934				3,152				9,351				9,456
General and administrative		5,178				4,838				13,675				12,064
Other		-				-				(492	)			-
Total operating expenses		10,658				10,444				29,207				28,490
Operating loss		(6,557	)			(6,345	)			(16,463	)			(17,112	)
Other income		3				5				2				2
Interest income, net		91				150				349				580
Net loss	$	(6,463	)		$	(6,190	)		$	(16,112	)		$	(16,530	)
Cumulative dividend on convertible preferred stock		(322	)			(328	)			(953	)			(984	)
Net loss attributable to common stockholders	$	(6,785	)		$	(6,518	)		$	(17,065	)		$	(17,514	)
Net loss per share attributed to common stockholders:
Basic	$	(0.07	)		$	(0.08	)		$	(0.19	)		$	(0.21	)
Diluted	$	(0.07	)		$	(0.08	)		$	(0.19	)		$	(0.21	)
Weighted average number of common shares and equivalents:
Basic		92,013,791				85,824,789				89,260,628				84,629,531
Diluted		92,013,791				85,824,789				89,260,628				84,629,531

STEREOTAXIS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share amounts)	September 30, 2025				December 31, 2024
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	10,506			$	12,217
Restricted cash - current		-				219
Accounts receivable, net of allowance of $621 and $582 at 2025 and 2024, respectively		5,333				3,824
Inventories, net		10,147				8,331
Prepaid expenses and other current assets		677				1,848
Total current assets		26,663				26,439
Property and equipment, net		3,156				3,573
Goodwill		3,764				3,764
Intangible assets, net		6,665				7,358
Operating lease right-of-use assets		5,059				5,483
Prepaid and other non-current assets		280				107
Total assets	$	45,587			$	46,724
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	4,681			$	5,668
Accrued liabilities		1,969				2,922
Deferred revenue		7,539				6,804
Current contingent consideration		5,558				5,638
Current portion of operating lease liabilities		623				570
Total current liabilities		20,370				21,602
Long-term deferred revenue		607				2,064
Long-term contingent consideration		7,016				6,126
Operating lease liabilities		4,960				5,436
Other liabilities		1,100				64
Total liabilities		34,053				35,292
Series A - Convertible preferred stock:
Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized, 21,121 and 21,458 shares outstanding at 2025 and 2024, respectively		5,268				5,352
Stockholders' equity:
Common stock, par value $0.001; 300,000,000 shares authorized, 91,088,439 and 85,326,557 shares issued at 2025 and 2024, respectively		91				85
Additional paid-in capital		584,218				567,926
Treasury stock, 4,015 shares at 2025 and 2024		(206	)			(206	)
Accumulated deficit		(577,837	)			(561,725	)
Total stockholders' equity		6,266				6,080
Total liabilities and stockholders' equity	$	45,587			$	46,724

FAQ

What were Stereotaxis (STXS) Q3 2025 total revenue and recurring revenue?

Total revenue was $7.5M and recurring revenue was $5.6M for Q3 2025.

How did STXS system revenue perform in Q3 2025 compared with Q3 2024?

Q3 2025 system revenue was $1.9M versus $4.4M in Q3 2024, a decline of about 57.6%.

What cash and liquidity did Stereotaxis (STXS) report at September 30, 2025?

Stereotaxis reported $10.5M cash and cash equivalents and would have $14.5M including the upcoming $4M financing tranche.

Did Stereotaxis (STXS) receive any regulatory clearances in November 2025?

Yes, Stereotaxis announced U.S. FDA clearance for the GenesisX robotic system and CE Mark/ FDA submission activity for Synchrony.

What guidance did Stereotaxis (STXS) give for Q4 2025 and full-year revenue?

The company expects Q4 2025 revenue to exceed $9M and full-year 2025 revenue growth to be over 20%.

How much revenue did MAGiC Sweep generate after launch for Stereotaxis (STXS)?

MAGiC Sweep generated over $300,000 in revenue within the first two months of launch.